Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients with Moderate to Severe Active Ulcerative Colitis

Journal of Clinical Gastroenterology

Volumn 49, Issue 7, 2015, Pages 582-588

  Jiang, Xue Liang ^a   Cui, Hui Fei ^b   Gao, Jing ^a   Fan, Hua ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

infliximab; low dose; ulcerative colitis

Indexed keywords

ANTINUCLEAR ANTIBODY; INFLIXIMAB; PLACEBO; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS; CHINA; COLITIS, ULCERATIVE; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED;

ADULT; CHINA; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INDUCTION CHEMOTHERAPY; INFLIXIMAB; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84937680619     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000319     Document Type: Article

References (20)

1. Wang Y, Ouyang Q. APDW 2004 Chinese IBD Working Group. Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients. J Gastroenterol Hepatol. 2007;22:1450-1455.
2. Maltese P, Palm L, Sfara C, et al. Glucocorticoid resistance in Crohn's disease and ulcerative colitis: an association study investigating GR and FKBPS gene polymorphisms. Pharmacogenomics J. 2012;12:432-438.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J med. 2005;353:2462-2476.
4. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Rev Gastroenterol Mex. 2006;71:351-401.
5. Clark M, Colombel JF, Feagan BC, et al. American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease. Gastroenterology. 2007;133:312-339.
6. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128:1805-1811.
7. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
8. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786.
9. Schroeder KW, Tremaine WJ, Ilstrup DM, et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317:1625-1629.
10. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
11. Ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
12. Kornbluth A, Sachar BD. The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guideline in adults: American College of Gastroenterology, practice parameters Committee. Am J Gastroenterol. 2010;105:501-523.
13. Jiang XL. The clinical observation of infliximab treatment for steroid-refractory ulcerative colitis. Chinese J Dig. 2010; 30:564-565.
14. Kornbluth A, Marion JF, Salomon P, et al. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol. 1995;20:280-284.
15. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23:429-448.
16. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
17. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
18. Hoentjen F, Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol. 2009;15:2067-2073.
19. Raval A, Akhaval-Toyserkani G, Brinker A, et al. Brief communication characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med. 2007;147:699-702.
20. Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51:1202-1207.